ClinicalTrials.gg
RecruitingNCT06417060Updated Aug 20, 2024

Caudal Anesthesia Versus Local Anesthesia in Hypospadias

An interventional study of Caudal block anesthesia and Dorsal penile block anesthesia in Hypospadias, Hypospadias, Coronal and Caudal Anesthesia, sponsored by Necmi Kadıoğlu Hospital. Recruiting at 3 sites in 3 countries. Open to male participants aged 6 Months to 48 Months. Per ClinicalTrials.gov, last updated 2024-08-20.

Sponsored by Necmi Kadıoğlu Hospital · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Aug 2024, 2 years 2 months ago, but the record still lists the study as recruiting.
  • Registered 11 months after the study started (first participant enrolled May 2023, registered May 2024).
  • Started May 2023; still recruiting 3 years 5 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
6 Months to 48 Months
Sex
Male
01

Study summary

Hypospadias is among the most common congenital genital malformations in boys and is typically treated through surgical intervention. During pediatric urological surgery, caudal anesthesia, also known as a caudal block, is frequently employed as a regional anesthetic technique. It has proven to be a safe and effective anesthetic approach in children, with a low rate of anesthesia-related complications. However, despite the low incidence of complications directly associated with the caudal block, there is limited and inconclusive evidence regarding its impact on surgical complications. Therefore, this randomized controlled superiority trial aims to evaluate whether the use of caudal anesthesia, compared to the dorsal penile block, is associated with an increased incidence of urethrocutaneous fistulas and glans dehiscence following hypospadias repair.

Read the detailed description

The rationale for conducting a comprehensive study arises from the limitations inherent in existing literature, primarily due to selection bias and the retrospective nature of current evidence, which fails to clarify whether caudal blocks lead to higher complication rates after hypospadias repair. To fill this knowledge gap and address the clinical uncertainty surrounding this issue, the only effective approach is to randomly assign patients undergoing hypospadias repair to receive either caudal or penile block anesthesia. The purpose of this pilot study is to evaluate the feasibility of a definitive trial and identify any methodological issues that must be resolved before committing significant resources to a full-scale study.

This pilot study will assess the feasibility of conducting a large, definitive, parallel-group, randomized controlled trial (RCT) to determine whether a dorsal penile block results in fewer postoperative complications than a caudal block in boys aged 6 to 48 months undergoing hypospadias repair.

Hypospadias repair will be performed under standardized analgesic administration, and participants may receive fentanyl (1-3 mcg/kg) at the anesthesiologist's discretion. Anesthesia will be induced via inhalation of air/nitrous oxide and sevoflurane. Based on a randomized allocation, patients will receive either a caudal anesthetic block (0.25% bupivacaine, 1 ml/kg, up to a maximum of 10 ml) or a dorsal penile block (bupivacaine without epinephrine, 10-20 ml/kg). All patients will receive antiemetic prophylaxis with dexamethasone (150 mcg/kg), ondansetron (50 mcg/kg), acetaminophen suppository (40 mg/kg), and intravenous morphine (0.02-0.1 mg/kg).

At discharge, patients will be prescribed oral morphine (0.2 mg/kg) every 4 hours as needed, Ditropan (0.2 mg/kg) every 12 hours as needed, Tylenol (15 mg/kg per dose) every 4 hours, or ibuprofen (10 mg/kg per dose) every 6 hours. Parents will administer these medications at their discretion. Trimethoprim (2 mg/kg) will also be prescribed until catheter removal.

02

Conditions studied

  • Hypospadias
  • Hypospadias, Coronal
  • Caudal Anesthesia
  • Children

Browse trials for

Keywords

  • Hypospadias
  • Caudal anesthesia
  • Urethrocutanous fistula
03

In context

Hypospadias

123 studies on the registry are indexed under Hypospadias; 34 are open to participants now.

This study's planned enrollment of 200 is above the median of 70 across 97 interventional studies indexed under Hypospadias.

Browse Hypospadias studies →

Lead sponsor

Necmi Kadıoğlu Hospital is the lead sponsor of 4 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Months to 48 Months
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged between 6 and 48 months
  • Distal hypospadias
  • Acceptance of participation

Exclusion criteria

Exclusion Criteria:

  • Midpenil hypospadias
  • Proximal hypospadias
  • Prior surgery
  • Comorbidity (diabetes, hypertention, cardiac pathology)
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Caudal block

    Anesthesia will be administered via inhalation induction with air/nitrous oxide and sevoflurane, followed by an injection of 0.25% bupivacaine (1 mL/kg) without epinephrine into the caudal canal, which is the sacral portion of the spinal canal.

    Drug: Caudal block anesthesia

  • Sham comparator
    Dorsal Penile Block Anesthesia

    Anesthesia will be administered using an inhalation induction method with air/nitrous oxide and sevoflurane, followed by the injection of 0.25% bupivacaine without epinephrine into the dorsal part of the penis.

    Drug: Dorsal penile block anesthesia

Interventions

  • DrugCaudal block anesthesia

    Anesthesia will be administered via inhalation induction with air/nitrous oxide and sevoflurane, followed by an injection of 0.25% bupivacaine (1 mL/kg) without epinephrine into the caudal canal, which is the sacral portion of the spinal canal.

  • DrugDorsal penile block anesthesia

    Anesthesia will be administered using an inhalation induction method with air/nitrous oxide and sevoflurane, followed by the injection of 0.25% bupivacaine without epinephrine into the dorsal part of the penis.

06

What researchers measure

Primary outcomes

  1. Post-operative complication rate

    A urethrocutaneous fistula (UCF) is characterized by an abnormal connection between the reconstructed urethra and the skin, situated between the original meatus and the tip of the penis. Glans dehiscence refers to the complete separation of the glans wings, which may or may not be connected by a strip of skin.

    Time frame: 1 year

07

Study locations

3 of 3 sites recruiting
  • Ss. Cyril and Methodius University in Skopje, Pediatric Surgery, Skopje, Macedonia, the former Yugoslav Republic of North Macedonia
    Skopje, North Macedonia
    Recruiting
    • Toni Risteski · Contact
    • Toni Risteski · Principal investigator
  • Ao Gk Medsi
    Moscow, Russian Federation
    Recruiting
    • Sergey Klyuev, MD · Contact
    • Sergey Klyuev, MD · Principal investigator
  • Necmi Kadioglu Esenyurt State Hospital
    Istanbul, 34430, Turkey
    Recruiting
    • Mustafa Azizoğlu · Contactmdmazizoglu@gmail.com · +905447448244
    • Mustafa Azizoglu, MD, PhD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2023 (actual). Primary completion is estimated for Aug 2024, 15 months after the start.

Of 60 non-industry interventional studies with no phase under Hypospadias, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 39. This study's planned 15 months is close to that.

Counting every sponsor, half of 60 studies reached it within 15 months; a quarter within 8 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2024
First posted
May 16, 2024
StartActual
May 25, 2023
Primary completionEst.
Aug 29, 2024
CompletionEst.
Aug 30, 2024
Last update
Aug 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06417060
Lead sponsor
Necmi Kadıoğlu Hospital
Responsible party
Mustafa Azizoğlu (MD, Necmi Kadıoğlu Hospital) — Principal investigator
First posted
May 16, 2024
Start date
May 25, 2023
Primary completion
Aug 29, 2024 (estimated)
Completion
Aug 30, 2024 (estimated)
Last update
Aug 20, 2024

Study contacts

Mustafa Azizoğlu, MD, PhD
Contact
mdmazizoglu@gmail.com
+905447448244
Mustafa Azizoğlu
principal investigator · Necmi Kadıoğlu State Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion